---
layout: post
title: "Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan"
date: 2026-02-05T11:44:00+00:00
source: PR Newswire Releases
source_url: https://www.prnewswire.com/news-releases/eisai-and-henlius-enter-into-exclusive-commercial-license-agreement-for-anti-pd-1-antibody-serplulimab-in-japan-302680126.html
significance: 7.20
---

<p>TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive...</p>

**Source:** [PR Newswire Releases](https://www.prnewswire.com/news-releases/eisai-and-henlius-enter-into-exclusive-commercial-license-agreement-for-anti-pd-1-antibody-serplulimab-in-japan-302680126.html)

**Published:** 2026-02-05 11:44:00 +0000

**Significance Score:** 7.20

[View original](https://www.prnewswire.com/news-releases/eisai-and-henlius-enter-into-exclusive-commercial-license-agreement-for-anti-pd-1-antibody-serplulimab-in-japan-302680126.html)
